Citation:Rugge M, Zaninotto G, Parente P, Zanatta L, Cavallin F, Germanà B, et al 2012

From Cancer Guidelines Wiki

Citation


Rugge M, Zaninotto G, Parente P, Zanatta L, Cavallin F, Germanà B, et al. Barrett's esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA). Ann Surg 2012 Nov;256(5):788-94; discussion 794-5. doi: 10.1097/SLA.0b013e3182737a7e. Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/23095623.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What are the risk factors for progression from non-dysplastic BO to high-grade dysplasia or adenocarcinoma?Professor David Whiteman B Med Sci, MBBS (Hons) PhD FAFPHMcompleted
What is the incidence of neoplasia in patients with BO?Associate Professor Freddy Sitascompleted
Are there groups of patients with non-dysplastic BO that require more frequent surveillance?Dr Henry Tocompleted
Are there groups of patients with BO that can be discharged from surveillance?Conjoint Associate Professor Philip Craigcompleted

Compare quality appraisals for each clinical question

Cited by

  1. Are there groups of patients with non-dysplastic BO that require more frequent surveillance?
  2. What are the risk factors for progression from non-dysplastic BO to high-grade dysplasia or adenocarcinoma?